Equities research analysts predict that bluebird bio, Inc. (NASDAQ:BLUE) will report $7.20 million in sales for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for bluebird bio’s earnings, with the highest sales estimate coming in at $9.70 million and the lowest estimate coming in at $5.32 million. bluebird bio posted sales of $1.55 million in the same quarter last year, which suggests a positive year over year growth rate of 364.5%. The business is scheduled to announce its next quarterly earnings results on Wednesday, February 28th.

According to Zacks, analysts expect that bluebird bio will report full year sales of $7.20 million for the current year, with estimates ranging from $36.57 million to $53.07 million. For the next fiscal year, analysts expect that the firm will report sales of $26.90 million per share, with estimates ranging from $13.00 million to $43.28 million. Zacks’ sales calculations are an average based on a survey of research firms that cover bluebird bio.

bluebird bio (NASDAQ:BLUE) last issued its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The company had revenue of $7.71 million during the quarter, compared to analysts’ expectations of $8.47 million. During the same quarter in the prior year, the business posted ($2.07) EPS. The company’s revenue for the quarter was up 397.4% compared to the same quarter last year.

Several brokerages recently issued reports on BLUE. Wells Fargo & Co restated an “outperform” rating and issued a $242.00 target price (up previously from $190.00) on shares of bluebird bio in a report on Tuesday, December 12th. SunTrust Banks lifted their price target on shares of bluebird bio to $223.00 and gave the stock a “buy” rating in a research note on Tuesday, December 12th. Barclays reiterated an “overweight” rating and set a $209.00 price target (up previously from $162.00) on shares of bluebird bio in a research note on Wednesday, December 13th. Maxim Group cut shares of bluebird bio from a “buy” rating to a “hold” rating and set a $200.00 price target on the stock. in a research note on Wednesday, December 13th. They noted that the move was a valuation call. Finally, CIBC began coverage on shares of bluebird bio in a research note on Thursday, December 21st. They set a “market perform” rating on the stock. Two analysts have rated the stock with a sell rating, ten have given a hold rating and thirteen have issued a buy rating to the company. bluebird bio has an average rating of “Hold” and a consensus price target of $157.45.

Shares of bluebird bio (BLUE) opened at $170.70 on Monday. bluebird bio has a fifty-two week low of $63.90 and a fifty-two week high of $222.03. The stock has a market cap of $7,820.00, a P/E ratio of -24.35 and a beta of 2.08.

In related news, Director Mark Vachon sold 7,000 shares of bluebird bio stock in a transaction on Monday, December 11th. The shares were sold at an average price of $216.64, for a total transaction of $1,516,480.00. Following the transaction, the director now owns 8,000 shares in the company, valued at approximately $1,733,120. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Nick Leschly sold 117,500 shares of bluebird bio stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $184.08, for a total transaction of $21,629,400.00. Following the transaction, the insider now owns 293,232 shares in the company, valued at approximately $53,978,146.56. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 222,268 shares of company stock worth $38,896,707. 3.90% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in BLUE. FMR LLC increased its holdings in bluebird bio by 9.6% in the 2nd quarter. FMR LLC now owns 6,713,949 shares of the biotechnology company’s stock valued at $705,301,000 after acquiring an additional 587,236 shares during the last quarter. Capital Research Global Investors increased its holdings in bluebird bio by 9.9% in the 2nd quarter. Capital Research Global Investors now owns 5,483,117 shares of the biotechnology company’s stock valued at $576,001,000 after acquiring an additional 493,072 shares during the last quarter. Vanguard Group Inc. increased its holdings in bluebird bio by 10.7% in the 2nd quarter. Vanguard Group Inc. now owns 3,559,102 shares of the biotechnology company’s stock valued at $373,884,000 after acquiring an additional 343,856 shares during the last quarter. BlackRock Inc. increased its holdings in bluebird bio by 4.3% in the 2nd quarter. BlackRock Inc. now owns 3,320,329 shares of the biotechnology company’s stock valued at $348,801,000 after acquiring an additional 138,141 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in bluebird bio by 11.7% in the 2nd quarter. Northern Trust Corp now owns 518,673 shares of the biotechnology company’s stock valued at $54,487,000 after acquiring an additional 54,142 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: “Analysts Anticipate bluebird bio, Inc. (BLUE) Will Post Quarterly Sales of $7.20 Million” was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/15/analysts-anticipate-bluebird-bio-inc-blue-will-post-quarterly-sales-of-7-20-million.html.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Get a free copy of the Zacks research report on bluebird bio (BLUE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.